157 Participants Needed

Cannabis for Chronic Back Pain

RN
AM
MA
Overseen ByMustafa Al-Mafrachi, MPH
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial examines how cannabis may help individuals with chronic back pain. Researchers aim to determine if cannabis can reduce the need for prescription opioids by acting as a pain reliever or by helping individuals lower their opioid doses. Participants will receive various combinations of THC (Tetrahydrocannabinol) and CBD, compounds found in cannabis, along with placebos. The trial may suit those who have experienced back pain for over three months and wish to reduce opioid use, provided they have not undergone major surgery recently or have other severe pain conditions. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potential new treatment options.

Will I have to stop taking my current medications?

The trial requires participants to stop using cannabis 14 days before the study and throughout the study. If you are currently using opioids, you must stop 14 days before the study and during the study if you are in the Analgesia Arm. Other medications like valproate, clobazam, clopidogrel, warfarin, barbiturates, and benzodiazepines are also not allowed.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that both THC and a combination of THC and CBD have been studied for safety in treating long-term pain. Studies suggest that side effects from THC are fairly common, occurring in about 26% of users, but these effects are usually mild and not serious. While some users may experience side effects, they are generally not severe.

For the THC/CBD combination, research indicates it is generally well-tolerated, especially compared to opioid painkillers. This combination has a good safety record, typically not causing serious side effects, with a low risk of addiction or misuse.

Overall, existing studies consider both treatments safe for most people. However, participants should discuss any concerns with healthcare providers before joining a trial.12345

Why are researchers excited about this trial's treatments?

Researchers are excited about using THC and THC/CBD for chronic back pain because these compounds offer a potential alternative to traditional painkillers like opioids and NSAIDs, which can have significant side effects and addiction risks. THC and CBD, derived from cannabis, work by interacting with the body's endocannabinoid system, possibly providing pain relief with a different mechanism of action than standard treatments. This approach could lead to effective pain management with fewer side effects, making it a promising option for those who have not found relief with current medications.

What evidence suggests that this trial's treatments could be effective for chronic back pain?

Research has shown that treatments using THC and a mix of THC/CBD can help reduce chronic back pain. In this trial, participants will receive different treatment sequences, including THC alone, a THC/CBD combination, and a placebo. One study found that people using THC reported significantly less pain compared to those who received a placebo. Another study found that a combination of THC and CBD reduced pain by 42% to 66%. These findings suggest that cannabis-based treatments can effectively manage chronic pain. Additionally, using both THC and CBD together may better reduce pain and the desire for opioids than using THC alone. Overall, these treatments appear promising for individuals with chronic back pain.13678

Who Is on the Research Team?

EL

Emily Lindley, PhD

Principal Investigator

University of Colorado, Denver

Are You a Good Fit for This Trial?

This trial is for adults with chronic, non-radiating spine pain lasting over 3 months. Participants must not have used cannabis or opioids recently and should be free from certain health conditions like cancer-related pain, neuropathic pain, recent major surgery, substance abuse disorders, significant mental health issues, cardiovascular disease, liver dysfunction or severe depression.

Inclusion Criteria

I have had back pain for 3 months or more that does not spread down my legs.
It seems like there might be a typo in your request. Could you please provide more details or clarify the criterion you'd like to have rewritten?

Exclusion Criteria

History of any mental health illness that in the opinion of the Investigator would compromise the safety of the participant
I suffer from nerve pain.
Your blood tests show important irregularities that the study doctor thinks are concerning.
See 32 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment - Analgesia Arm

Participants receive daily treatment with an oral cannabis solution in a crossover design for 6 weeks per treatment period

18 weeks
Weekly visits

Treatment - Reduction Arm

Participants receive daily treatment with an oral cannabis solution or placebo for 13 weeks

13 weeks
Weekly visits

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Placebo
  • THC
  • THC/CBD

Trial Overview

The study tests the safety and effectiveness of oral cannabis (THC/CBD combination or THC alone) compared to a placebo in reducing chronic spine pain and potentially decreasing opioid use. The goal is to see if cannabis can serve as an alternative to opioids for long-term pain management.

How Is the Trial Designed?

8

Treatment groups

Experimental Treatment

Placebo Group

Group I: Reduction Arm: THC/CBDExperimental Treatment1 Intervention
Group II: Analgesia Arm: THC/CBD, then THC, then PlaceboExperimental Treatment3 Interventions
Group III: Analgesia Arm: THC/CBD, then Placebo, then THCExperimental Treatment3 Interventions
Group IV: Analgesia Arm: THC, then Placebo, then THC/CBDExperimental Treatment3 Interventions
Group V: Analgesia Arm: THC (tetrahydrocannabinol), then THC/CBD (cannabidiol), then PlaceboExperimental Treatment3 Interventions
Group VI: Analgesia Arm: Placebo, then THC/CBD, then THCExperimental Treatment3 Interventions
Group VII: Analgesia Arm: Placebo, then THC, then THC/CBDExperimental Treatment3 Interventions
Group VIII: Reduction Arm: PlaceboPlacebo Group1 Intervention

THC is already approved in United States, Canada, European Union for the following indications:

🇺🇸
Approved in United States as Dronabinol for:
🇨🇦
Approved in Canada as Dronabinol for:
🇪🇺
Approved in European Union as Dronabinol for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Colorado, Denver

Lead Sponsor

Trials
1,842
Recruited
3,028,000+

Institute of Cannabis Research

Collaborator

Trials
2
Recruited
130+

Colorado Department of Public Health and Environment

Collaborator

Trials
11
Recruited
10,000+

Citations

a phase 3 randomized placebo-controlled trial

Similarly, the rate of participants with a ≥50% pain reduction (32.2% versus 22.8%; P = 0.010) and a ≥2-point pain reduction (46.9% versus 35.6 ...

NCT06454669 | Dronabinol as an Adjunct for Reducing Pain

Collectively, these data suggest that cannabinoids may be more effective for chronic rather than acute pain conditions. ... Low Back PainChronic PainBack Injuries.

The Efficacy of Cannabis in Reducing Back Pain - PMC - NIH

At all time-points during the 8 hour session, there was a statically significant reduction in pain in both THC groups when compared to the placebo group.

Long-Term Cannabis Therapy for Chronic Low Back Pain

Short-term data suggest promise: a 2-week study of 249 CLBP patients found THC-dominant edibles significantly reduced pain, and observational ...

Efficacy of Dronabinol as an Adjuvant Treatment for ...

Results of the Phase I study showed that patients who received dronabinol experienced decreased pain intensity and increased satisfaction compared with placebo.

Long-term and serious harms of medical cannabis and ... - PMC

Very low certainty evidence suggests that adverse events are common (prevalence: 26.0%; 95% CI 13.2% to 41.2%) among users of medical cannabis for chronic pain.

Safety Considerations in Cannabinoid-Based Medicine - PMC

Cannabinoid-based medicines are associated with safety risks which should be assessed in the context of potential therapeutic benefits.

Dronabinol Useful for Chronic Pain: A Case Report

central neuropathic pain showed “that dronabinol is a safe long-term treatment option” with “no signs of drug abuse and only one possible.